Pharmacogenetics in drug development

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Philosophical Transactions of the Royal Society B: Biological Sciences

• Publication date

  2005-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1098/rstb.2005.1688PMID 16096107PMCID PMC1569527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical Genetics: A Marker for Stevens-Johnson SyndromeChung W-H, Hung S-I, Hong H-S, et al (Chang Gung Mem Hosp, Taipei, Taiwan; Inst of Biomedical Sciences, Taipei, Taiwan) Nature 428:486, 2004§

  2006cited by this paper
• Pharmacogenetics and Drug Development

  2005cited by this paper
• Towards Molecular Medicine

  2005cited by this paper
• Disease-specific target selection: a critical first step down the right road.

  2005cited by this paper
• Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

  2004cited by this paper
• Serotonin transporter: gene, genetic disorders, and pharmacogenetics.

  2004cited by this paper
• Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment

  2004cited by this paper
• CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia

  2004cited by this paper
• Molecular signatures for diagnosis of infection: application of microarray technology

  2004cited by this paper
• A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone

  2004cited by this paper
• Protein Kinase Inhibitors: Insights into Drug Design from Structure

  2004cited by this paper
• Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.

  2004cited by this paper
• Pharmacogenetics and drug development: the path to safer and more effective drugs

  2004cited by this paper
• Antiviral drugs: Third strike against HIV enzymes

  2004cited by this paper
• Clinical Experience with Trastuzumab (Herceptin)

  2003cited by this paper
• Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

  2003cited by this paper
• Pharmacogenetics of the major polymorphic metabolizing enzymes

  2003cited by this paper
• The price of innovation: new estimates of drug development costs.

  2003cited by this paper
• Pharmacophylogenomics: genes, evolution and drug targets

  2003cited by this paper
• Functional neuroimaging of genetic variation in serotonergic neurotransmission

  2003cited by this paper
• Pharmacogenetics goes genomic

  2003cited by this paper
• Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone

  2003cited by this paper
• Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids.

  2003cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  2002cited by this paper
• Genome-based pharmacogenetics and the pharmaceutical industry

  2002cited by this paper
• Integrated approaches to therapeutic target gene discovery.

  2002cited by this paper
• Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.

  2002cited by this paper
• The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings.

  2001cited by this paper
• Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation.

  2001cited by this paper
• Towards molecular medicine; reminiscences of the haemoglobin field, 1960–2000

  2001cited by this paper
• Culture and psychopharmacology.

  2001cited by this paper
• The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.

  2001cited by this paper
• Effect of Polymorphism of the β2-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma

  2001cited by this paper
• Implications of the human genome for understanding human biology and medicine.

  2001cited by this paper
• &bgr;2-Adrenoceptor Polymorphism Determines Vascular Reactivity in Humans

  2000cited by this paper
• The impact of genomics on drug discovery.

  2000cited by this paper
• Genomic Control for Association Studies

  1999cited by this paper
• Use of unlinked genetic markers to detect population stratification in association studies.

  1999cited by this paper
• Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia

  1999cited by this paper
• Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

  1999cited by this paper
• Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics

  1999cited by this paper
• Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.

  1999cited by this paper
• Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty

  1999cited by this paper
• Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.

  1998cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.

  1998cited by this paper
• Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

  1998cited by this paper
• Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

  1997cited by this paper
• Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype.

  1997cited by this paper
• Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.

  1997cited by this paper
• The evolving science of pharmacogenetics: clinical and ethnic perspectives.

  1996cited by this paper
• Moderne Probleme der Humangenetik

  1959cited by this paper

• Tailored animal Treatments: Insights into pharmacogenomics

  2025cites this paper
• Role of Personalized Medicine in Clinical Practice: An Overview of Current and Future Perspectives

  2024cites this paper
• Relevance of pharmacogenetics and pharmacogenomics in veterinary clinical practice: A review.

  2023cites this paper
• Historical Perspective of Drug Discovery and Development

  2021cites this paper
• Application of Pharmacogenomics in Drug Discovery and Development

  2020cites this paper
• Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences

  2020cites this paper
• The Place of Pharmacogenetics in Person-centered Medicine: A Bioethical Reflection

  2019cites this paper
• Genetics of vascular dementia – review from the ICVD working group

  2017cites this paper
• Emerging Themes in Drug Resistance

  2017cites this paper
• A REVIEW ON THE ROLE OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT

  2016cites this paper
• Pharmacogenetics and Pharmacogenomics : Applications in Drug Development and Therapeutics

  2016cites this paper
• Emergence of Pharmacogenomics in Academic Medicine and Public Health in Jordan: History, Present State and Prospects

  2015cites this paper
• Pharmacogenetics and Pharmacogenomics: A Brief Introduction

  2015cites this paper
• Pharmacogenetics, Pharmacogenomics and Ayurgenomics for Personalized Medicine: A Paradigm Shift

  2015cites this paper
• Akreditasi PP IAI – 2 SKP Application of Pharmacogenomics on Drug Discovery and Development

  2014cites this paper
• Application of Pharmacogenomics on Drug Discovery and Development

  2014cites this paper
• Omics Approaches and Applications in Clinical Trials

  2013cites this paper
• The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system

  2013cites this paper
• Understanding pharmacology in humans: Phase I and Phase II (data generation).

  2011cites this paper
• The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery

  2011cites this paper
• Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach

  2010cites this paper
• Coriell Personalized Medicine Collaborative®: a prospective study of the utility of personalized medicine.

  2010cites this paper
• La farmacogenomica en medicina

  2009cites this paper
• Role of pharmacogenomics in drug discovery and development

  2008influential citation
• Bioethics, Business Ethics, and Science: Bioinformatics and the Future of Healthcare

  2008cites this paper
• Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.

  2008cites this paper
• Genetics of antipsychotic treatment emergent weight gain in schizophrenia.

  2006cites this paper
• Introduction: genetic variation and human health

  2005cites this paper
• Recent Advance Study on Pharmacogenomics: A REVIEW

  year unknowncites this paper